AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesDisciplines and OccupationsAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth CareGeographicals
Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationTransplantation ConditioningGraft vs Host DiseaseTransplantation ChimeraBone Marrow TransplantationGraft SurvivalTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsTissue DonorsStem CellsGraft vs Leukemia EffectMyeloablative AgonistsBusulfanTreatment OutcomeVidarabineRemission InductionRecurrenceGraft vs Tumor EffectHistocompatibility TestingRadiation ChimeraLymphocyte TransfusionHematopoietic Stem CellsCord Blood Stem Cell TransplantationImmunosuppressive AgentsWhole-Body IrradiationLeukemiaLeukemia, Myeloid, AcuteMultiple MyelomaRetrospective StudiesCombined Modality TherapySiblingsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCytomegalovirus InfectionsMinor Histocompatibility AntigensLymphocyte DepletionHistocompatibilitySalvage TherapyLiver TransplantationDisease-Free SurvivalAntilymphocyte SerumSurvival AnalysisMyelodysplastic SyndromesSurvival RateVirus ActivationChimerismNeoplasm, ResidualPrecursor Cell Lymphoblastic Leukemia-LymphomaMelphalanHematopoietic Stem Cell MobilizationMesenchymal Stem Cell TransplantationTime FactorsHepatic Veno-Occlusive DiseaseCyclophosphamideAntigens, CD34T-LymphocytesAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusCell TransplantationAnemia, AplasticLiving DonorsHLA AntigensAcute DiseaseKidney TransplantationPrimary MyelofibrosisHematologic DiseasesEmbryonic Stem CellsFollow-Up StudiesTransplantation ImmunologyBlood DonorsImmunosuppressionLeukemia, Myeloid, Accelerated PhasePrognosisGraft RejectionAntibodies, NeoplasmRoseolovirus InfectionsAdult Stem CellsCytarabineLeukemia, MyeloidGranulocyte Colony-Stimulating FactorBenzamidesImmunocompromised HostLymphoproliferative DisordersAntineoplastic AgentsFusion Proteins, bcr-ablBone Marrow CellsHodgkin DiseaseNuclear FamilyReceptors, Purinergic P2X5PyrimidinesFlow CytometryCell DifferentiationTransplantation, IsogeneicLymphoma, Non-HodgkinInfectionLeukocyte TransfusionGanciclovirCyclosporine
HSCTTransplantGraft-versus-Marrow transplantationHaematopoietic stem cell transplantChemotherapyTransplantsHematologicProgenitorGvHDUmbilical cord blood tran2022Autologous hematopoietic stem cell transMatched unrelated donorHaploidenticalMyeloablativeImmuneRecipientsTransplanting allogeneic hematopoieticNeutrophil and platelet engraftmentChimerismRecipientPeripheral blood stemHuman leukocyPatient's own cellsRegimenRelapse after allogeneicAplasticEarly engraftmentSickle cell diPlateletClinically relevant levelsSyngeneicSevere Combined ImmunodCord Blood Transplantation2020GeneticReactivationUnderwentCancerBone marrow stem cellReconstitutionProcedureTotal body irradiation folTherapiesGeneticallyBlood stem cellsGrafts
HSCT41
  • Hematopoietic stem cell transplantation (HSCT) results in the alteration of several components of the immune system. (medscape.com)
  • Patients who undergo HSCT experience a sequential suppression of host defenses, resulting in varying infectious risk at different phases of the transplantation process. (medscape.com)
  • Right now, hematopoietic stem cell transplantation (HSCT) is the foremost dependable healing treatment with amazing comes about for patients with HLAmatched family or disconnected givers. (alliedacademies.org)
  • We performed a review chart audit of 12 children who experienced allogeneic HSCT for WAS to report our involvement. (alliedacademies.org)
  • The most common adverse event following allogeneic hematopoietic stem cell transplantation (HSCT) is graft-versus-host disease (GVHD), which can increase morbidity and mortality in HSCT patients. (oncologynurseadvisor.com)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only curative modality for many hematological disorders. (hindawi.com)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) and coronavirus disease 2019 (COVID-19) infection can both lead to severe cytokine release syndrome (sCRS) resulting in critical illness and death. (akjournals.com)
  • In this single institution, preliminary comparative case-series study we compared clinical and laboratory co-variates as well as response to tocilizumab (TCZ)-based therapy of 15 allogeneic-HSCT- and 17 COVID-19-associated sCRS patients. (akjournals.com)
  • Reaction to a TCZ plus posttransplant cyclophosphamide (PTCY) consolidation therapy in the allogeneic-HSCT-associated sCRS group yielded significantly inferior long-term outcome as compared to TCZ-based therapy in the COVID-19-associated group ( P = 0.003). (akjournals.com)
  • Serum levels of cytokines and chemokines show similar changes in allogeneic-HSCT- and COVID-19-associated sCRS with marked elevation of interleukin-6 (IL-6), regulated upon activation normal T-cell expressed and secreted (RANTES), monocyte chemoattractant protein-1 (MCP-1) and interferon γ -induced protein 10 kDa (IP-10) levels. (akjournals.com)
  • In addition, levels of IL-5, IL-10, IL-15 were also elevated in allogeneic-HSCT-associated sCRS. (akjournals.com)
  • Our multi-cytokine expression data indicate that the pathophysiology of allogeneic-HSCT and COVID-19-associated sCRS are similar therefore the same clinical grading system and TCZ-based treatment approaches can be applied. (akjournals.com)
  • Allogeneic hematopoietic stem-cell transplantation (HSCT) may provide cure in this scenario. (unisr.it)
  • We compared outcomes of HSCT from HLA-identical (HLA-id, n = 1654) sibling or haploidentical (Haplo, n = 389) donors in patients with R/R-AML, performed during the period 2007-2015. (unisr.it)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative therapy for sickle cell disease (SCD). (haematologica.org)
  • Serum citrulline was quantified by liquid chromatography in blood samples collected from consecutive patients who received an allogeneic HSCT in our institution between July 2014 and November 2019. (confex.com)
  • There is a paucity of data examining the tolerance and outcome of hematopoietic stem cell transplantation (HSCT) for relapse after tositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • There is a paucity of data examining the tolerance andoutcome of hematopoietic stem cell transplantation (HSCT) for relapse aftertositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Successful outcome following hematopoietic stem cell transplantation (HSCT) is ultimately determined by the ability to achieve sustained engraftment and immune reconstitution, control of graft-versus-host disease (GVHD), and in patients with hematological malignancy the complete eradication of abnormal or malignant cells. (johnshopkins.edu)
  • His research focus is on haematopoietic stem cell transplantation (HSCT) and translational research of normal and malignant stem cells. (edu.au)
  • The ability to correct genetic hematopoietic diseases by gene therapy has a number of advantages over current therapies that involve allogeneic hematopoietic stem cell transplantation (HSCT). (nih.gov)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
  • The biological questions with MonoMAC center around whether the individual leukocyte compartments that are lost in MonoMAC (B-lymphocytes, NK cells, and monocytes) will be constituted with HSCT, and whether the residual recipient T-lymphocytes will represent an impediment to engraftment. (nih.gov)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) involves the infusion of stem cells following administration of high-dose chemotherapy or total body irradiation for either tumor control or to prevent solid transplant rejection. (gvhdhub.com)
  • Allo-HSCT is an important treatment strategy, which allows administration of myeloablative therapy and the elimination of cancer cells by the transplanted donor T and natural killer (NK) cells in a phenomenon known as the graft- versus -leukemia (GvL) effect. (gvhdhub.com)
  • The overall and sustained clinical benefit of omidubicel makes it an important addition to the options for allogeneic HSCT. (gamida-cell.com)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) appears safe for treatment of hepatitis-associated aplastic anemia, according to a study results reported in the International Journal of Hematology . (hematologyadvisor.com)
  • The study was a retrospective analysis of 37 adult patients who received their first allogeneic HSCT for hepatitis-associated aplastic anemia between 1985 and 2014. (hematologyadvisor.com)
  • According to the authors, "our results suggested that allogeneic HSCT for hepatitis-associated aplastic anemia would provide favorable survival. (hematologyadvisor.com)
  • Since then, allogeneic hematopoietic stem cell transplantation (HSCT) has evolved to become a frequently used and effective therapy for many hematologic malignancies. (longdom.org)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • The growing need for haematopoietic stem cell transplantation (HSCT) is reflected in the increasing number of transplants performed globally each year. (bvsalud.org)
Transplant44
  • About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. (wikipedia.org)
  • Risks of infection also vary with the type of transplant, the indication for transplantation, and other host factors. (medscape.com)
  • The transplant procedure requires the harvesting of hematopoietic stem cells from a donor. (medscape.com)
  • Allogeneic transplants involve grafts from a genetically nonidentical donor of the same species and are the transplant type most often used in children. (oncologynurseadvisor.com)
  • We noted that the numbers of CD4+, CD4+ CD45RA+, and CD4+ CD45RO+ T cells after transplant in the RIST group were significantly lower than those in the CST group (P = 0.0001 for both the comparisons). (psu.edu)
  • Ramos CA " Striking the right balance: optimizing conditioning regimens for unrelated donor bone marrow transplant for severe aplastic anemia. . (bcm.edu)
  • The transplant of blood stem cells or bone marrow will be infused one to three days after the last chemotherapy or radiation dose. (ucsfhealth.org)
  • Generally, before receiving this kind of transplant, the patient will undergo a course of treatments to remove their own stem cells and prepare the body for the new stem cells. (fda.gov)
  • Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. (sagepub.com)
  • To avoid relapsing and declination of the immune system, Stem Cell transplant is reported to be encouraged. (stemcelline.com)
  • The result of Stem Cell transplant shows that the success rate hits up to 60.7% while only 39.3% remain in relapsed cases. (stemcelline.com)
  • The article covers the following topic:- leukemia introduction, Stem cell transplant for treatment of Leukemia, benefits of transplant, types of transplant, complications, and how to be a stem cell donor. (stemcelline.com)
  • Topics:- Leukemia therapy with stem cell transplant, advantages of transplant, different types of transplant, side effects, and how to become a stem cell donor. (stemcelline.com)
  • The world is bestowed with a profound technique, namely, Stem Cell therapy or Stem Cell Transplant which helps in restoring your immune system and curing the disease at once. (stemcelline.com)
  • Autologous transplant - This transplant involves the extraction of stem cells from the patient's blood or bone marrow during the most stable condition of the patient. (stemcelline.com)
  • Allogeneic transplant- The transplantation involves infusing stem cells, extracted from a donor who is genetically matched with the patient. (stemcelline.com)
  • Though this transplant is quite preferable around the world, still there might occur many complications in case the donor is mismatched. (stemcelline.com)
  • Genetic variation in both patient and donor can significantly affect transplant outcome by causing disparity for transplant antigens, and by altering the function of immune response genes that control cellular activation and inflammation. (johnshopkins.edu)
  • The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. (seattlechildrens.org)
  • Professor Ma holds leadership or scientific membership positions in a number of national and international scientific communities including the World Network for Blood & Marrow Transplantation (a WHO affiliated NGO), the AsiaPacific BM Transplant and the Royal College of Pathology of Australasian Quality Assurance Programme. (edu.au)
  • To try to make transplantation safer we are using lower doses of the medications used in preparing the patient for the transplant. (zhihuiya.com)
  • This is known as an allogeneic matched sibling transplant. (zhihuiya.com)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
  • Third, use of autologous hematopoietic stem cells would be expected to enhance immune reconstitution after transplant. (nih.gov)
  • 27, 2022-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with solid and hematological cancers and other serious diseases, today announced updated one-year post-transplant data presented on omidubicel at the 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings (TCT), being held in Salt Lake City, UT , April 23-26, 2022 . (gamida-cell.com)
  • Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies (blood cancers), for which it has been granted Breakthrough Status and orphan drug designation by the FDA. (gamida-cell.com)
  • Dr. Tisdale and his colleagues recently completed a modified bone marrow transplant strategy for the first time in adult patients with sickle cell disease. (nih.gov)
  • In a recent study, they demonstrated that they could transplant bone marrow cells from HLA-matched sibling donors without needing to completely destroy the patient's immune system. (nih.gov)
  • The standard treatment is blood stem cell transplant, but outcomes are dependent on finding the disease early. (umn.edu)
  • This single-institution, phase II study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe osteopetrosis (OP). (umn.edu)
  • Therefore, we sought to translate these results to a clinically relevant canine-to-canine allogeneic transplant model for Duchenne muscular dystrophy (DMD) and determine if CXCR4 is important for donor cell engraftment. (biomedcentral.com)
  • Intramuscular injection of donor muscle-derived cells into chimeric cxmd recipients restored dystrophin expression for at least 24 weeks in the absence of post-transplant immunosuppression, indicating that cell transplantation may be a viable therapeutic option for muscular dystrophy. (biomedcentral.com)
  • Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. (scielo.org)
  • Two patients died early, and the remaining patients experienced neutrophil engraftment in a median of 17 days (range, 10-36) post-transplant. (hematologyadvisor.com)
  • As a stem cell transplant patient, you have new opportunities for a healthy and full life. (cdc.gov)
  • Stem cells from your own body (also called an autologous transplant). (cdc.gov)
  • Stem cells from a donor (also called an allogeneic transplant). (cdc.gov)
  • A transplant using stem cells from a donor increases your risk for fungal infection more than a transplant that uses stem cells from your own body. (cdc.gov)
  • As you recover from your transplant, your white blood cell count can become very low, also known as neutropenia pdf icon [PDF - 4 pages] . (cdc.gov)
  • Fungal infections can happen days, weeks, or months after the stem cell transplant. (cdc.gov)
  • Some types of fungal infections are more common than others in stem cell transplant patients. (cdc.gov)
  • Aspergillosis is the most common type of fungal infection in stem cell transplant patients, followed by Candida infection and mucormycosis, but other types of fungal infections are also possible. (cdc.gov)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Transplant infectious disease : an official journal of the Transplantation Society 2022 6 24 (4): e13879. (cdc.gov)
Graft-versus-6
  • Currently, my work aims to establish strategies to reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation without exacerbating graft-versus-host disease or interfering with donor stem cell engraftment. (stanford.edu)
  • The greater the mismatch between donor and recipient, the higher the risk of graft versus host disease (GVHD). (medscape.com)
  • Similar to all approved umbilical cord products , the label carries a Boxed Warning for infusion reactions, graft versus host disease (GvHD - a condition that occurs when donor bone marrow or stem cells attack the graft recipient), engraftment syndrome (characterized by a noninfectious fever and rash), and graft failure (occurs when new cells do not produce white blood cells, red blood cells and platelets). (fda.gov)
  • In a related editorial, Sandhya Kharbanda and Christopher Dvorak, both from the University of California in San Francisco, USA, suggest that "we may be seeing the beginning of the end of allogeneic HCT for Hurler syndrome", along with the risk of rejection or graft-versus-host-disease. (institut-servier.com)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • Abstract Introduction: Graft-versus-host disease (GVHD) is a serious complication in allogeneic transplantation. (scielo.org)
Marrow transplantation16
Haematopoietic stem cell transplant1
  • The study, published in The New England Journal of Medicine, involved eight children with mucopolysaccharidosis type I, Hurler variant, who lacked a suitable donor for allogeneic haematopoietic stem-cell transplantation (HCT), the current standard of care. (institut-servier.com)
Chemotherapy9
  • For example, people who have stem cell transplantation go through intensive chemotherapy before treatment. (clevelandclinic.org)
  • Chemotherapy, radiation, or both are initiated prior to transplantation to enable engraftment of the transplanted cells, decrease tumor size, and reduce immunoreactivity of the recipient. (oncologynurseadvisor.com)
  • An environment for GVHD is formed when antigen-presenting cells are activated by the patient's disease and the pretreatment destruction of cells caused by chemotherapy and radiotherapy. (oncologynurseadvisor.com)
  • The product is intended for use in adults and pediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy). (fda.gov)
  • Hematopoietic stem cell transplantation is also sometimes used for solid tumors (eg, some germ cell tumors) that respond to chemotherapy. (msdmanuals.com)
  • Bone marrow transplants from healthy donors are used successfully to treat certain blood cancers for which the course of the disease is so severe that the destruction of the patient's own immune system through high-dose chemotherapy and radiation seems an effective compromise. (nih.gov)
  • It permits the administration of exceedingly high doses of chemotherapy, a practice that becomes viable due to the subsequent infusion of the patient's own stem cells. (medistateinternational.com)
  • This twofold approach not only harnesses the power of potent chemotherapy but also safeguards against bone marrow deficiency by replenishing the patient's stem cell count following the chemotherapy phase. (medistateinternational.com)
  • Mobilization human CD34+ cells for the purpose of donor (allogeneic) transplantation after high-dose chemotherapy is currently performed using a 4-5-day treatment cycle with G-CSF and a 1-2 day apheresis procedure. (biokine.com)
Transplants11
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants. (wikipedia.org)
  • Donors for allogeneic transplants may be related or unrelated to the recipient. (medscape.com)
  • In syngeneic transplants, the donor is the identical twin of the recipient. (medscape.com)
  • Allogeneic transplants are further categorized by the degree of human leukocyte antigen (HLA) match between the donor and recipient. (medscape.com)
  • Transplants from HLA-matched siblings are associated with a lower risk of GVHD and faster recovery of the recipient's immune system following transplantation. (medscape.com)
  • Identical twin allogeneic transplants are called syngeneic transplants. (ucsfhealth.org)
  • There are two types of stem cell transplants, namely. (stemcelline.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Stem cell transplants have many benefits, but they also have risks. (cdc.gov)
  • Because stem cell transplants destroy and rebuild your immune system, they increase your risk for fungal infections. (cdc.gov)
  • The idea to use transplants of dopa- ment of protocols that allow generation of fully functional mine-producing cells to substitute for the lost midbrain and safe midbrain dopamine neurons from stem cells. (lu.se)
Hematologic2
  • We have investigated 30 allogeneic stem cell transplantation suffering from different types of leukemia (n=18) or non-malignant hematologic disorders (n=12) by close molecular monitoring during 1-12 months after transplantation. (celljournal.org)
  • NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies. (sagepub.com)
Progenitor9
  • In principle, transplantation of mesenchymal progenitor cells would attenuate or possibly correct genetic disorders of bone, cartilage and muscle, but clinical support for this concept is lacking. (nih.gov)
  • The etiology of bone marrow failure (BMF) includes defective stem/progenitor cells and/or stroma/accessory cells/growth factors, as well as deficient nonspecific nutrients or, as in the case of acquired aplastic anemia, immune-mediated abnormalities. (medscape.com)
  • Inherited bone marrow failure syndromes (IBMFS) are usually the result of intrinsic stem cell/progenitor defects. (medscape.com)
  • The pharmacokinetics of BUSULFEX were studied in 59 patients participating in a prospective trial of a BUSULFEX-cyclophosphamide preparatory regimen prior to allogeneic hematopoietic progenitor stem cell transplantation. (nih.gov)
  • Altering and reintroducing the haematopoietic stem and progenitor cells (HSPCs) of children with Hurler syndrome results in "extensive" correction of metabolic abnormalities, report researchers. (institut-servier.com)
  • Embryonic myogenic progenitor cells express CXCR4, G-protein coupled cell surface receptor, and migrate towards regions of SDF-1 expression during limb muscle development, suggesting that CXCR4/SDF-1 plays a role in muscle cell homing. (biomedcentral.com)
  • We have recently demonstrated in a Phase I study in healthy volunteers that single dose of the CXCR4 antagonist BL-8040 induces a rapid and robust mobilization and mega dose collection of human CD34+ stem and progenitor cells. (biokine.com)
  • BACKGROUND:Umbilical cord blood has become an important source of hematopoietic stem and progenitor cells for therapeutic applications. (duke.edu)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
GvHD17
  • The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GvHD. (wikipedia.org)
  • GvHD occurs when the donor's immune system's white blood cells reject the recipient. (wikipedia.org)
  • In GVHD, the donated stem cells view the recipient cells as foreign and attack recipient cells. (medscape.com)
  • GVHD has been reported after syngeneic and autologous transplantation but is rare. (medscape.com)
  • Treatment focuses on blocking the expansion of donor T cells, as GVHD develops from the expansion of these cells. (oncologynurseadvisor.com)
  • CD20 antagonists deregulate B cells, which are believed to contribute to the pathogenesis of GVHD. (oncologynurseadvisor.com)
  • When CD20 antagonists decrease the amount of circulating B cells, the body may not produce as many cytotoxic T cells that can potentially induce GVHD. (oncologynurseadvisor.com)
  • GVHD occurs in about 30-50% and 70% of recipients allografted from matched related and matched unrelated donors, respectively [ 1 ]. (hindawi.com)
  • The degree of HLA disparity between donor and recipient is a well-known and widely accepted independent risk factor for GVHD development [ 2 ]. (hindawi.com)
  • Acute GVHD occurs most frequently 30-40 days after engraftment. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • GVHD, which can be a serious and fatal complication, is an immune reaction that is initiated by donor T cells in response to recipient alloantigens. (johnshopkins.edu)
  • 1. Definition: GVHD develops when the donor's immune cells mistakenly attack the patient's normal cells. (drcremers.com)
  • One to two days before your stem cell infusion, you'll take a regimen of drugs to help prevent GVHD. (drcremers.com)
  • Acute GVHD can occur soon after the transplanted cells begin to appear in the recipient. (drcremers.com)
  • Causes of mortality in those patients were severe viral pneumonia, post-transplantation hemophagocytic syndrome and meningeal GVHD refractory to ruxolitinib. (scielo.org)
Umbilical cord blood tran2
  • Eighty-seven percent of subjects who were randomized to receive Omisirge achieved neutrophil recovery with a median of 12 days following treatment with the product, compared to 83% of subjects who were randomized to receive umbilical cord blood transplantation and who achieved neutrophil recovery with a median of 22 days. (fda.gov)
  • Engraftment failure and delays, likely due to diminished cord blood unit (CBU) potency, remain major barriers to the overall success of unrelated umbilical cord blood transplantation (UCBT). (duke.edu)
20222
  • Gamida Cell initiated a rolling Biologics License Application (BLA) submission for omidubicel in the first quarter of 2022 and is on-track to complete submission of all modules of the BLA in the second quarter of 2022. (gamida-cell.com)
  • In total, Gamida Cell is presenting two oral and six poster presentations at TCT 2022, including an oral presentation that was selected as a TCT Best Abstract. (gamida-cell.com)
Autologous hematopoietic stem cell trans2
Matched unrelated donor4
  • A 33-year-old man in Madrid, Spain, with chronic myeloid leukemia in lymphoid blastic phase underwent allogeneic stem cell transplantation (SCT) from a matched unrelated donor in 2011. (cdc.gov)
  • Four patients were alive withno evidence of disease (three matched unrelated donor and one matched relateddonor). (cancernetwork.com)
  • This is know as matched unrelated donor transplantation. (zhihuiya.com)
  • On the day before the BMT, patients in the matched unrelated donor group also receive a low-dose of whole-body radiation. (zhihuiya.com)
Haploidentical3
  • The three main categories of allogeneic transplantation are HLA identical, HLA mismatched, and haploidentical. (medscape.com)
  • Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy? (nih.gov)
  • This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who lack a suitable HLA-matched sibling donor. (umn.edu)
Myeloablative2
Immune19
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • This is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. (clevelandclinic.org)
  • Therefore, immune reconstitution after RIST might be different from that after conventional stem cell transplantation (CST). (psu.edu)
  • This radiation therapy is intended to destroy remaining cancer cells and further suppress the immune system. (ucsfhealth.org)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • These treatments require further medication to improve the immune system deteriorated during the period and sometimes even end up with destroying the healthy blood cells. (stemcelline.com)
  • In addition, this procedure gives therapeutic advantages of a fetal environment like acceptance of unmatched allogeneic donor cells within the pre HDAC9 list immune fetus and engraftment devoid of the will need for conditioning regimen within the rapidly expanding bone marrow (BM) niche. (betadesks.com)
  • Rodent models of IUHSCT have also proved useful, specifically together with the availability of recipients lacking particular immune cells. (betadesks.com)
  • However, the IUHSCT of human donor cells into immune competent models, mice (five) or sheep (six, 7), leads to only low levels of engraftment in those recipients that do engraft, which can be also a important reflection of limitations facing patients in actual clinical settings. (betadesks.com)
  • Her clinical and translational research explores whether certain immune cells called natural killer (also known as NK cells) can prevent relapse and treat high-risk cancers. (seattlechildrens.org)
  • This study uses transplantation to treat patients with problems in their immune system. (zhihuiya.com)
  • The immune system cells come from the bone marrow where they grow from special cells called stem cells. (zhihuiya.com)
  • Giving patients stem cells from someone else may help to cure many patients with certain immune diseases. (zhihuiya.com)
  • This lets the cells of the donor go into the bone marrow and produce normal immune cells. (zhihuiya.com)
  • The graft usually comes from a human leukocyte antigen (HLA)-matched donor and contains hematopoietic cells as well as immune cells, including T lymphocytes. (gvhdhub.com)
  • The issue of immune tolerance is, of course, central to transplantation research. (nih.gov)
  • Dr. Tisdale has an active research program in trying to characterize tolerance and create conditions in which patients will more easily tolerate donor cells and tissues without the need for destroying the immune system or perpetual use of immunosuppressant drugs. (nih.gov)
  • We used a clinically acceptable regimen of hematopoietic stem cell transplantation to establish mixed donor/host blood cell chimerism and immune tolerance in a canine model of Duchenne muscular dystrophy ( cxmd ) [ 9 ]. (biomedcentral.com)
  • Improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation. (duke.edu)
Recipients4
  • In preparation for receipt of the stem cells, recipients undergo myeloablation to eliminate their own myeloid cells. (medscape.com)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • In a Phase II study single-agent treatment with BL-8040 showed similar efficacy and non-inferiority in recipient engraftment, with all transplanted recipients successfully engrafting with BL-8040-mobilized grafts. (biokine.com)
Transplanting allogeneic hematopoietic1
  • Dr. Flake was the first to investigate the therapeutic potential of in utero stem cell transplantation (IUSCT) for treating hematopoietic and other genetic disorders by demonstrating that transplanting allogeneic hematopoietic cells early in gestation achieve clinically significant levels of hematopoietic chimerism. (chop.edu)
Neutrophil and platelet engraftment2
  • The median times for neutrophil and platelet engraftment were 13.5 and 12 days, respectively, and did not differ between the two cohorts. (nature.com)
  • The middle times to neutrophil and platelet engraftment were 19 days (run, 13 to 27) and 18.5 days (extend, 12 to 31), separately. (alliedacademies.org)
Chimerism6
  • Chimerism analysis - testing of short tandem repeat regions to assess donor bone marrow engraftment. (ouh.nhs.uk)
  • In contrast to the expected mixed chimerism that usually occurs in the absence of conditioning, we found in our patients 100% donor cell engraftment based on fluorescence in situ hybridization (FISH) and microsatellite techniques. (nih.gov)
  • So Analysis of donor chimerism has become a routine method for documentation of engraftment after allogeneic stem cell transplantation. (celljournal.org)
  • The PCR-based assay was extremely sensitive and did not need donor and recipient samples for the assessment of chimerism. (celljournal.org)
  • Neutrophil engraftment was achieved on day 12 post-SCT, with complete donor chimerism. (cdc.gov)
  • We are also evaluating whether we achieve sufficient donor chimerism to reverse the MDS. (nih.gov)
Recipient10
  • In the two cases with ABO incompatibility, erythroid engraftment was evidenced by blood group conversion from recipient to donor type. (nih.gov)
  • In autologous transplantation, the donor and recipient is the same individual. (medscape.com)
  • When the donor is someone other than the recipient, the procedure is described as allogeneic transplantation. (medscape.com)
  • The harvested stem cells are processed before infusion into the recipient. (medscape.com)
  • PCR techniques using a set of amelogenin gene primer were preformed on whole WBC and/or BMA samples, and in some cases on isolated T-cell and granulocytes subsets of recipient patients. (celljournal.org)
  • Cytotoxic T cells mount a response on the body and target recipient cells are lysed. (oncologynurseadvisor.com)
  • As such, the murine anemic model and severe combined immunodeficient (SCID) model demonstrate superior engraftment than normal mice following IUHSCT, similar for the observation with SCID individuals exactly where donor cells have an advantage more than recipient HSC for populating the niche (3, four). (betadesks.com)
  • Immunological hurdles to achieving clinically relevant levels of engraftment that have lately been identified involve maternal alloantibodies, maternal T cells, and recipient NK cells (8-10). (betadesks.com)
  • Herein, we propose that access to the fetal BM HSC niche must also be of prominence, for engraftment in the absence of conditioning regimens is often a competitive method between donor and recipient HSCs for populating limited niche space (11, 12). (betadesks.com)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
Peripheral blood stem1
Human leukocy1
  • A human leukocyte antigen (HLA)-identical sibling donor is ideal, followed by an HLA-matched sibling donor. (msdmanuals.com)
Patient's own cells3
  • Each dose is patient-specific, containing healthy stem cells from an allogeneic pre-screened donor, meaning it comes from a different individual rather than using the patient's own cells. (fda.gov)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • In cases where such donors are not available, the process can extend to non-related donors or even a patient's own cells, demonstrating the flexibility and innovation inherent in this field. (medistateinternational.com)
Regimen2
  • The primary object of the conditioning regimen for allogeneic reduced-intensity stem cell transplantation (RIST) is immunosuppression to achieve stable engraftment of donor cells, rather than bone marrow ablation. (psu.edu)
  • All patients except two who received reduced intensity had severe mucositis.Reversible veno-occlusive disease of the liver also developed in two patients.There was one death from graft-vs-host disease and no regimen-related mortality.Engraftment was prompt, with a median recovery of absolute neutrophil count to ³ 500/µL of 12 days (range: 11-18 days). (cancernetwork.com)
Relapse after allogeneic1
  • Since approximately 30% of leukemia patients relapse after allogeneic BMT using total body irradiation (TBI)-based preparative regimens, treatment intensity may be suboptimal. (nature.com)
Aplastic2
Early engraftment1
  • The test can be used routinely, alone or in conjunction with STR-PCR, to analyze BM and PBL of post allogenic sex- mismatched BMT to detect early engraftment or rejection and for observing kinetics of engraftment. (celljournal.org)
Sickle cell di4
  • The Cellular and Molecular Therapeutics Laboratory, led by Dr. John F. Tisdale, is working on multiple strategies both in the laboratory and in the clinic to cure sickle cell disease by repairing or replacing the precursor bone marrow cells that give rise to sickled red blood cells. (nih.gov)
  • In addition, strategies to correct the underlying mutation which causes sickle cell disease are being pursued utilizing newly developed gene editing tools, and work in the laboratory to develop methods for efficient editing of hematopoietic stem cells is underway. (nih.gov)
  • Sickle cell disease (SCD) has its roots in genetic mutations that cause a single amino acid change in the β-globin chain of hemoglobin A and thereby confer protection against malaria. (nih.gov)
  • 2019 sickle cell disease guidelines by the American Society of Hematology: methodology, challenges, and innovations. (nih.gov)
Platelet3
  • Engraftment speed after RIST was fast and seven of 22 patients did not require platelet transfusion. (psu.edu)
  • Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de Lima M, Lichtiger B " Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. . (bcm.edu)
  • The goal is to support you with red blood cell and platelet transfusion until you are producing cells again. (ucsfhealth.org)
Clinically relevant levels1
  • He continues to study the requirements to engraftment and developed a pre-clinical canine model of IUSCT in which he has achieved clinically relevant levels of donor engraftment with a goal of prenatal treatment of hemoglobinopathies. (chop.edu)
Syngeneic1
  • eg, bone, bone marrow, and skin grafts) Genetically identical (syngeneic [between monozygotic twins]) donor tissue (isografts) Genetically. (msdmanuals.com)
Severe Combined Immunod1
Cord Blood Transplantation1
  • Single-Nucleotide Polymorphisms Within Non-HLA Regions Are Associated With Engraftment Effectiveness for Patients With Unrelated Cord Blood Transplantation. (cdc.gov)
20201
Genetic6
  • Autologous transplantation is feasible when the patient's bone marrow is normal and there are no relevant genetic conditions. (medscape.com)
  • Allogeneic transplantation is also used for the management of certain genetic abnormalities. (medscape.com)
  • Genetic experiments demonstrate R-loop increases in cells lacking APOBEC3B and decreases in cells overexpressing APOBEC3B. (bvsalud.org)
  • In-utero hematopoietic stem cell transplantation (IUHSCT) provides the opportunity for transplanting cells from an allogeneic donor into the early fetus to appropriate numerous genetic problems of hematological, immunological, and metabolic etiologies, that may very well be diagnosed prenatally (1). (betadesks.com)
  • For this research we are using the genetic disease, canine leukocyte adhesion deficiency (CLAD), as a model for applying advances in understanding of stem cell biology to enhance gene transfer into the hematopoietic stem cells. (nih.gov)
  • We initially search a potential donor within the siblings of the patient by determining HLA type, true genetic identity card of the cells. (longdom.org)
Reactivation1
Underwent1
Cancer9
  • Healthcare providers consider several factors before recommending allogeneic stem cell transplantation to treat blood disorders or cancer. (clevelandclinic.org)
  • Blood cancers are a form of cancer caused by uncontrolled growth of cells in the blood, disrupting the ability of blood cells to perform their normal functions. (fda.gov)
  • Leukemia is a cancer of blood cells and bone marrow, which means it results in excessive growth of white blood cells. (stemcelline.com)
  • Stem cells are a kind of special cell possessing the ability to develop into any kind of cell as required, these are being frequently used to replace the cancer cells with healthy ones. (stemcelline.com)
  • It should be administered under the supervision of a qualified physician who is experienced in allogeneic hematopoietic stem cell transplantation, the use of cancer chemotherapeutic drugs and the management of patients with severe pancytopenia. (nih.gov)
  • Professor Ma heads the Blood, Stem Cell and Cancer Research Programme at St Vincent's Centre for Applied Medical Research, Sydney. (edu.au)
  • This allows us to administer a therapeutic dose of cells that may help cancer patients live longer better lives. (gamida-cell.com)
  • While stem cell transplantation often finds its place in addressing leukemia and cancer cases, its scope extends far beyond these realms, particularly in childhood ailments. (medistateinternational.com)
  • Evidence suggests that the CXC-chemokine receptor-4 (CXCR4) pathway plays a major role in cancer cell homing and metastasis and in shaping the tumor microenvironment (TME), and thus represents a potential target for cancer therapy. (biokine.com)
Bone marrow stem cell1
Reconstitution1
  • However, the reconstitution of CD20+ B cells was faster in the RIST group (P = 0.0001). (psu.edu)
Procedure3
Total body irradiation fol1
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
Therapies5
  • Bio My research is focused on using preclinical models to develop novel therapies which improve outcomes for patients receiving allogeneic hematopoietic stem cell transplantation. (stanford.edu)
  • Ramos CA, Asgari Z, Liu E, Yvon E, Heslop HE, Rooney CM, Brenner MK, Dotti G " An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. . (bcm.edu)
  • Our NAM-enabling technology is designed to enhance the number and functionality of targeted cells, enabling us to pursue a curative approach that moves beyond what is possible with existing therapies. (gamida-cell.com)
  • Gamida Cell is pioneering a proprietary NAM-enabled immunotherapy pipeline of diverse potentially curative cell therapies for patients with solid tumor and blood cancers and other serious blood diseases. (gamida-cell.com)
  • Gene and cell therapies present novel alternatives to disease management, offering the promise of a single treatment and a lifelong cure. (bvsalud.org)
Genetically1
  • Usually, the donor may be a sibling or any blood-related person, just in case no one is available then, the nearest genetically equivalent person can also donate to the patient. (stemcelline.com)
Blood stem cells3
Grafts1
  • The Cord Blood Apgar: a novel scoring system to optimize selection of banked cord blood grafts for transplantation (CME). (duke.edu)